{
    "description": "A randomized controlled trial investigating the efficacy and safety of upadacitinib in patients with rheumatoid arthritis over a 5-year period.",
    "metadata": {
      "authors": ["Dr. John Doe", "Dr. Jane Smith"],
      "publication_date": "2022-06-15",
      "journal": "Journal of Rheumatology",
      "impact_factor": 5.6
    },
    "extracted_features": [
      {
        "description": "Primary Outcome: Reduction in Disease Activity Score (DAS28) after 24 weeks",
        "value": "Significant reduction (p<0.05)"
      },
      {
        "description": "Secondary Outcome: Maintenance of remission at 5 years",
        "value": "78% of patients remained in remission"
      },
      {
        "description": "Adverse Events",
        "value": "Common: Nausea, Headache, Mild Infections; Serious: 2% experienced serious adverse events such as severe infections"
      },
      {
        "description": "Statistical Significance",
        "value": "p-value for primary outcome < 0.05, confidence interval: 95%"
      }
    ],
    "questions": [
      {
        "question": "What is the 5-year safety data of upadacitinib in the SELECT-EARLY trial?",
        "answer": "The 5-year safety data indicated that 2% of patients experienced serious adverse events, primarily severe infections, while common adverse events included nausea, headache, and mild infections."
      },
      {
        "question": "What were the primary outcomes of the clinical trial for rheumatoid arthritis?",
        "answer": "The primary outcome was a significant reduction in Disease Activity Score (DAS28) after 24 weeks of treatment with upadacitinib (p<0.05)."
      }
    ],
    "outcome": "Positive",
    "outcome_reasoning": "The trial showed both efficacy in reducing disease activity and a manageable safety profile over 5 years."
  }
  